Journal of Translational Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44-7360-538437

Short Communication - Journal of Translational Research (2022) Volume 6, Issue 2

Assessing nanomedical research translational signs and technological possibilities.

Magro Lucia*

Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy

*Corresponding Author:
Magro Lucia
Department of Clinical and Experimental Medicine
University of Cataniac
95123 Catania, Italy
E-mail:[email protected]

Received:28-Feb-2022, Manuscript No. AATR-22-109; Editor assigned: 02-Mar-2022, PreQC No. AAT-22-109; Reviewed:17-Mar-2022, QC No. AATR-22-109; Revised:22-Mar-2022, Manuscript No. AATR-22-109 (R); Published:29-Mar-2022, DOI:10.35841/aatr-6.2.109

Citation: Lucia M. Assessing nanomedical research translational signs and technological possibilities. Am J Transl Res. 2022;6(2):109

Visit for more related articles at Journal of Translational Research

Introduction

Nanotechnology's application in healthcare has the potential to have a significant impact on human health in terms of illness prevention, diagnosis, and treatment. The development and design of Nano Particulate Nano Medicines (NNMs) for drug delivery is one component of the Nano medicine field that has gotten a lot of interest recently. Solubilisation, passive targeting, active targeting, and triggered release are some of the processes used by NNMs to deliver pharmaceuticals. The NNM strategy tries to improve treatment efficacy, lower therapeutically effective doses, and/or lower the risk of systemic adverse effects. Several experimental challenges must be overcome in order for a NNM to progress from the bench to the bedside. The current trends and problems in the clinical translation of NNMs, as well as prospective avenues for translational development and marketing, will be discussed in this study. Biological problems, large-scale production, biomedical applications and safety, property rights (IP), government controls, and overall cost-effectiveness in contrast to present medicines will all be discussed [1].

Nano medicine is a branch of medicine that employs nanotechnology to extremely specialised medicinal interventions for illness prevention, diagnosis, and therapy. Researchers, academics, funding organisations, government, and regulatory bodies have all paid close attention to the use of nanotechnology in medicine over the last few decades. The design and implementation of Nano Particulate Nano Medicines (NNMs) for delivery of drugs, which are most typically given through parenteral (especially intravenous) administration, has gotten a lot of interest in the Nano medicine sector. NNMs are designed to improve medication therapeutic index by delivering them by a variety of processes, including solubilisation, passively targeting, effective in reducing stress, and triggered release. Nano encapsulation allows for the protection of fragile chemicals that readily breakdown in biological settings, as well as the delivery of molecules with physicochemical features that severely limit their aqueous solubility and thus systemic bioavailability. Targeted drug delivery and triggered NNM release have been found to improve compound therapeutic index by enhancing the in vivo fate of drug molecules, leading to more effective delivery to the target site with reduced accumulating in many healthy body sites. NNMs have also been investigated for their capacity to increase target cell uptake and improve intracellular trafficking, both of which are processes that are sometimes necessary when they have been localised in target tissues [2].

NNMs are frequently researched in order to increase drug targeting to specific disease sites (i.e., site-specific drug delivery) and/or reduce localisation in non-target tissues. The great majority of NNMs in preclinical and clinical development, as well as those in current usage, are used to treat a range of malignancies and tumours. In recent years, the use of NNM-based therapeutics for drug targeting in non-cancer illnesses has grown. NNMs have been developed in particular to address the therapeutic problem of effectively controlling inflammatory illnesses by utilising the underlying biology of these diseases. Arthritis, inflammatory disease, asthma, neurological disorders, diabetes, and neurodegenerative illnesses are among the non-cancerous inflammatory conditions that have been studied with NNM therapy [3].

NNM clinical translation is a costly and time-consuming procedure. In comparison to traditional formulation technology, which uses free medication dispersion in a base, NNM technology is usually significantly more sophisticated. From gadolinium-based systems for Magnetic Resonance (MRI) to quantum dots for optical microscopy, nanomaterials have a long and noteworthy history as contrast agents in imaging applications. Tracking therapies is one of the areas where nanomaterials can and are having an impact on getting treatments to the clinic. For example, the use of nanomaterials in cellular therapies such as the infusion of mesenchyme stem cells or Mesenchyme Stromal Cells (MSCs) allows for high-resolution cell tracking in clinical trials [4].

Overall, nanotechnology's application in medicine has the potential to have a significant impact on human health. It has been proposed as a way to speed up the development of personalised medicine for certain patient subgroups, in which treatment is matched to the patient's genetic and illness profile. For best therapeutic advantages, the physicochemical parameters of the delivery system can also be changed based on the severity of the condition. This concept would make a major difference in how we treat patients. However, as highlighted in this study, a number of challenges must be solved before this can happen, ranging from our basic understanding of the biology of certain illnesses and the biological interactions of NNMs in patients to manufacturing commercialization barriers. Finally, in order for a preparation to have the potential to be transformed into a clinically relevant treatment, researchers must consider decreasing the complexity of NNMs while also considering the ultimate dose form for human usage. To produce therapeutically translatable nanosized therapies, nanoparticle design and production must reduce complexity to the bare minimum required for pathophysiology or medicinal needs [5].

References

  1. Arroyave A, Gembicky M, Rheingold AL, et al. Aqueous Stability and Ligand Substitution of a Layered Cu (I) Isocyanide-Based Organometallic Network Material with a Well-Defined Channel Structure. Inorg Chem. 2020;59(17):11868-78.
  2. Indexed at, Google Scholar, Cross Ref

  3. Sadjadi S. Nanocatalytic wastewater treatment system for the removal of toxic organic compounds. Nano materials. 2014;401-27.
  4. Indexed at, Google Scholar, Cross Ref

  5. Murday JS, Siegel RW, Stein J, et al. Translational nanomedicine: Status assessment and opportunities.. Nanomedicine. 2009;5(3):251-73.
  6. Indexed at, Google Scholar, Cross Ref

  7. Boucetta H, Bitounis D, Servant A, et al. Purified graphene oxide dispersions lack in vitro cytotoxicity and in vivo pathogenicity. Adv Healthc Mater. 2013;2(3):433-41.
  8. Indexed at, Google Scholar, Cross Ref

  9. Chernova T, Murphy FA, Galavotti S, et al. Long-fiber carbon nanotubes replicate asbestos-induced mesothelioma with disruption of the tumor suppressor gene Cdkn2a (Ink4a/Arf). Curr Biol. 2017;27(21):3302-14.
  10. Indexed at, Google Scholar, Cross Ref

Get the App